Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Diosmin is a flavonoid glycoside that strengthens venous walls by enhancing vascular endothelial function and reducing capillary permeability. Clinical trials demonstrate it reduces chronic venous disease symptoms by approximately 50%, including pain, swelling, and leg heaviness.
Origin & History
Diosmin is a flavonoid glycoside primarily derived from citrus fruits, especially oranges (Citrus sinensis) and other Citrus species, where it occurs naturally in small amounts. It is typically produced by extracting hesperidin from citrus peels and converting it to diosmin via enzymatic or chemical processes, such as treatment with iodine or benzyl chloride followed by purification.
Research Narrative (Provisional)
Clinical evidence includes a multicenter RCT (n=72) showing 450mg bioavailable diosmin significantly improved pain and venous severity scores versus placebo over 8 weeks, and a noninferiority trial (PMID 32206351) demonstrating 600mg nonmicronized diosmin matched 900mg micronized diosmin plus hesperidin for CVD efficacy. A post-surgical RCT (PMID 38109425) found reduced swelling after knee arthroplasty, while an ongoing trial (NCT06125002) is investigating effects on exercise-induced muscle soreness.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Diosmin is a flavonoid glycoside (molecular formula C₂₈H₃₂O₁₅, MW 608.54 g/mol) and is not a macronutrient source — it provides negligible calories, protein, fat, fiber, or carbohydrates at therapeutic doses. Bioactive compound: Diosmin (diosmetin-7-O-rutinoside), a flavone glycoside derived from the aglycone diosmetin (3',5,7-trihydroxy-4'-methoxyflavone) linked to the disaccharide rutinose (rhamnose-glucose). Typical therapeutic dose: 450–900 mg/day, most commonly supplied as micronized purified flavonoid fraction (MPFF) containing ~90% diosmin and ~10% other flavonoids (hesperidin, linarin, isorhoifolin, diosmetin). Natural sources: Found in citrus peel (especially Citrus sinensis and Citrus limon) at concentrations of ~1–4 mg/g dry weight; also present in Barosma betulina (buchu) and Scrophularia nodosa. Commercially, most diosmin is semi-synthesized from hesperidin (extracted from citrus peels) via catalytic oxidation. Bioavailability notes: Native diosmin has very poor oral bioavailability (<10%) due to low aqueous solubility (~0.005 mg/mL). Micronization (particle size reduction to <2 µm) significantly improves absorption, increasing bioavailability approximately 2-fold compared to non-micronized forms. After oral ingestion, diosmin is hydrolyzed by intestinal flora to its aglycone diosmetin, which is the primary absorbed metabolite. Diosmetin undergoes extensive phase II metabolism (glucuronidation and sulfation) in the gut wall and liver. Peak plasma concentrations of diosmetin conjugates occur at ~1–2 hours post-dose for micronized formulations. Plasma half-life of metabolites is approximately 11–31 hours. Urinary recovery of metabolites is ~50% within 48 hours. Key associated micronutrients in MPFF formulations: Hesperidin (~10%, ~50–100 mg per dose), which contributes synergistic antioxidant and anti-inflammatory activity. No significant vitamin or mineral content at standard supplemental doses.
Reported Mechanism (Provisional)
Diosmin enhances venous tone by increasing norepinephrine sensitivity in venous smooth muscle and inhibiting catechol-O-methyltransferase (COMT) enzyme activity. It reduces capillary permeability by strengthening endothelial tight junctions and decreasing inflammatory mediators like histamine and prostaglandins. The compound also improves lymphatic drainage by stimulating lymphatic contractility and reducing lymphatic vessel hyperpermeability.
Clinical Narrative (Provisional)
A randomized controlled trial with 72 participants over 8 weeks showed diosmin reduced chronic venous disease symptoms by approximately 50%, including significant improvements in pain, swelling, and leg heaviness. A multicenter RCT demonstrated statistically significant improvements in venous clinical severity scores and patient satisfaction (p<0.001). Multiple studies consistently show diosmin effectively reduces lower-extremity swelling and improves overall venous function. The evidence is considered strong for venous insufficiency applications, though most studies have been conducted over relatively short timeframes of 8-12 weeks.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.